Hansa Biopharma AB/Skr HNSA
07:00
08:00
09:00
10:00
11:00
1D1W1MYTD1Y5YMAX
About Hansa Biopharma AB
Hansa Biopharma AB is a biopharmaceutical company headquartered in Lund, Sweden, operating within the healthcare industry. The company specializes in developing immunomodulatory enzyme technology to treat rare immunological conditions. Its leading product, Idefirix, is designed to enable kidney transplants in highly sensitized patients by cleaving immunoglobulin G antibodies. Hansa Biopharma's strategic focus includes expanding its technology platform and gaining regulatory approvals internationally. The company's innovative approach in enzyme-based therapies positions it to address unmet medical needs in transplantation and autoimmunity.
Ticker
Skr HNSA
Sector
Primary listing
XSTO
Employees
122
Headquarters
Lund, Sweden
Website
HNSA Metrics
BasicAdvanced
kr 2.9bn
-
-kr 7.71
1.50
-
Price and volume
Market cap
kr 2.9bn
Beta
1.5
52-week high
kr 42.98
52-week low
kr 22.82
Average daily volume
375k
Financial strength
Current ratio
3.63
Quick ratio
3.602
Long term debt to equity
-412.672
Total debt to equity
-414.966
Interest coverage (TTM)
-2.55%
Profitability
EBITDA (TTM)
-567.776
Gross margin (TTM)
59.67%
Net profit margin (TTM)
-363.06%
Operating margin (TTM)
-299.37%
Effective tax rate (TTM)
-0.35%
Revenue per employee (TTM)
kr 1,560,000
Management effectiveness
Return on assets (TTM)
-38.17%
Return on equity (TTM)
153.85%
Valuation
Price to revenue (TTM)
13.504
Price to book
-10.58
Price to tangible book (TTM)
-5.72
Price to free cash flow (TTM)
-4.641
Free cash flow yield (TTM)
-21.55%
Free cash flow per share (TTM)
-6.18
Growth
Revenue change (TTM)
4.84%
Earnings per share change (TTM)
-18.14%
3-year revenue growth (CAGR)
8.67%
10-year revenue growth (CAGR)
49.50%
3-year earnings per share growth (CAGR)
-18.90%
10-year earnings per share growth (CAGR)
12.75%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hansa Biopharma AB stock?
Hansa Biopharma AB (HNSA) has a market cap of Skr2.9B as of May 14, 2026.
What is the P/E ratio for Hansa Biopharma AB stock?
The price to earnings (P/E) ratio for Hansa Biopharma AB (HNSA) stock is 0 as of May 14, 2026.
Does Hansa Biopharma AB stock pay dividends?
No, Hansa Biopharma AB (HNSA) stock does not pay dividends to its shareholders as of May 14, 2026.
When is the next Hansa Biopharma AB dividend payment date?
Hansa Biopharma AB (HNSA) stock does not pay dividends to its shareholders.
What is the beta indicator for Hansa Biopharma AB?
Hansa Biopharma AB (HNSA) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.